ES2097905T3 - Agentes terapeuticos para el tratamiento de la resistencia multidroga de canceres. - Google Patents

Agentes terapeuticos para el tratamiento de la resistencia multidroga de canceres.

Info

Publication number
ES2097905T3
ES2097905T3 ES92905338T ES92905338T ES2097905T3 ES 2097905 T3 ES2097905 T3 ES 2097905T3 ES 92905338 T ES92905338 T ES 92905338T ES 92905338 T ES92905338 T ES 92905338T ES 2097905 T3 ES2097905 T3 ES 2097905T3
Authority
ES
Spain
Prior art keywords
treatment
therapeutic agents
drug resistance
cancer multi
dihydrocinchonine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92905338T
Other languages
English (en)
Inventor
Bruno Chauffert
Philippe Genne
Gilles Gutierrez
Rolland-Yves Mauvernay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Debiopharm SA
Patrinove
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Debiopharm SA
Patrinove
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CH57691A external-priority patent/CH682050A5/fr
Priority claimed from CH352291A external-priority patent/CH683238A5/fr
Application filed by Debiopharm SA, Patrinove, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Debiopharm SA
Application granted granted Critical
Publication of ES2097905T3 publication Critical patent/ES2097905T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE UTILIZA CINCONINA, DIHIDROCINCONINA O HIDROCINCONINA COMO SUSTANCIA INHIBIDORA DE LA RESISTENCIA MULTIDROGA EN EL TRATAMIENTO DE TUMORES CANCEROSOS MEDIANTE AGENTES CITOTOXICOS. EN PARTICULAR SE UTILIZA LA CINCONINA, LA DIHIDROCINCONINA O LA HIDROCINCONINA EN LA PREPARACION DE COMPOSICIONES FARMACEUTICAS DESTINADAS AL TRATAMIENTO DE TUMORES CANCEROSOS QUE DESARROLLAN EL FENOMENO DE LA RESISTENCIA MULTIDROGA. APLICACION EN EL TRATAMIENTO DE LOS CANCERES EN EL HOMBRE.
ES92905338T 1991-02-25 1992-02-24 Agentes terapeuticos para el tratamiento de la resistencia multidroga de canceres. Expired - Lifetime ES2097905T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH57691A CH682050A5 (en) 1991-02-25 1991-02-25 Use of cinchonine, di:hydro:cinchonine or hydro:quinidine
CH352291A CH683238A5 (fr) 1991-12-02 1991-12-02 Hydroquinidine, comme agent thérapeutique et son utilisation dans une composition pharmaceutique.

Publications (1)

Publication Number Publication Date
ES2097905T3 true ES2097905T3 (es) 1997-04-16

Family

ID=25685005

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92905338T Expired - Lifetime ES2097905T3 (es) 1991-02-25 1992-02-24 Agentes terapeuticos para el tratamiento de la resistencia multidroga de canceres.

Country Status (9)

Country Link
US (1) US5635515A (es)
EP (1) EP0526608B1 (es)
JP (1) JPH06505991A (es)
AT (1) ATE146361T1 (es)
AU (1) AU649787B2 (es)
CA (1) CA2081343C (es)
DE (1) DE69215999T2 (es)
ES (1) ES2097905T3 (es)
WO (1) WO1992014467A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
US5866699A (en) * 1994-07-18 1999-02-02 Hybridon, Inc. Oligonucleotides with anti-MDR-1 gene activity
CA2221444A1 (en) * 1996-01-31 1997-08-07 Steven B. Hansel A method of making pharmaceutically active taxanes orally bioavailable
FR2764509A1 (fr) * 1997-06-11 1998-12-18 Debiopharm Sa Compositions pharmaceutiques contenant du dichlorhydrate de cinchonine
FR2784580B1 (fr) * 1998-10-16 2004-06-25 Biosepra Inc Microspheres de polyvinyl-alcool et procedes de fabrication de celles-ci
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
WO2003041128A2 (en) * 2001-11-07 2003-05-15 Pharmacia Corporation Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
US6916627B2 (en) * 2002-11-27 2005-07-12 St. Jude Children's Research Hospital ATM kinase compositions and methods
US7108992B2 (en) * 2002-11-27 2006-09-19 St. Jude Children's Research Hospital ATM kinase compositions and methods
WO2008105872A1 (en) * 2007-02-28 2008-09-04 Cancure Laboratories, Llc Drug combinations to treat drug resistant tumors
WO2014145386A2 (en) * 2013-03-15 2014-09-18 University Of Florida Research Foundation Incorporated Novel allosteric inhibitors of thymidylate synthase
CA2891633C (en) * 2014-02-12 2015-12-22 Adam Mickiewicz University Application of cinchona alkaloid derivatives as cytotoxic compounds
CN105796558A (zh) * 2014-12-31 2016-07-27 天津大学 辛可宁在制备抗肿瘤药物的用途
WO2016209688A1 (en) 2015-06-24 2016-12-29 University Of Florida Research Foundation, Incorporated Compositions for the treatment of cancer and uses thereof
US11066421B1 (en) 2021-02-09 2021-07-20 Ares Pharmaceuticals, LLC Synthetic cinchona alkaloids against cancer
US11649232B2 (en) 2021-05-10 2023-05-16 Ares Pharmaceuticals, LLC Synthetic dimeric cinchona alkaloids against cancer
TR2022004099A2 (tr) * 2022-03-17 2023-09-21 Mugla Sitki Kocman Ueniversitesi Idari Mali Isler Baskanligi Beyi̇n tümörleri̇ni̇n tedavi̇si̇nde hi̇droki̇ni̇di̇n molekülünün kullanimi
WO2023230702A1 (en) * 2022-06-03 2023-12-07 University Of Manitoba Novel antimicrobial compounds isolated using a machine learning model trained on a high-throughput antibacterial screen
KR20240119419A (ko) * 2023-01-30 2024-08-06 고려대학교 산학협력단 카이랄 자성 나노코일 및 이의 합성방법

Also Published As

Publication number Publication date
EP0526608B1 (fr) 1996-12-18
AU649787B2 (en) 1994-06-02
DE69215999D1 (de) 1997-01-30
EP0526608A1 (fr) 1993-02-10
US5635515A (en) 1997-06-03
CA2081343C (fr) 2003-09-16
DE69215999T2 (de) 1997-07-03
AU1206292A (en) 1992-09-15
CA2081343A1 (fr) 1992-08-26
WO1992014467A1 (fr) 1992-09-03
JPH06505991A (ja) 1994-07-07
ATE146361T1 (de) 1997-01-15

Similar Documents

Publication Publication Date Title
ES2097905T3 (es) Agentes terapeuticos para el tratamiento de la resistencia multidroga de canceres.
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
IS4073A (is) Nýtt fjölvirknislyf gegn aukningu mótstöðu
MX9301929A (es) Derivados de pirimidina y procedimientos para su preparacion.
AR020019A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de cancer de mama
ATE261974T1 (de) Hoch-lipophile campothecin-derivate
TR200000576T1 (tr) Lipozomal kapsüllenmiş taksan uygulanması için bir yöntem
AR012172A2 (es) Composiciones farmaceuticas que comprenden analogos de lactacistina y uso de los mismos para la fabricacion de un medicamento
RU93051543A (ru) Производные акридина, способ получения, фармацевтическая композиция и способ лечения злокачественных опухолей
DK0490077T3 (da) Antisense-oligonukleotider til behandling af cancer
UY27943A1 (es) Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos
AR022860A1 (es) Derivados de camptotecina que poseen actividad antitumoral
BRPI0415525A (pt) derivados de imidazola e seu uso como agentes farmacêuticos
ES8505519A1 (es) Un procedimiento para la preparacion de 14-fluoromorfinanos utiles como analgesicos, narcoticos y-o agentes anorexicos.
BR0115162A (pt) Tratamentos antitumorais eficazes
DK1017675T3 (da) Stærkt lipofile camptothecinderivater
MX9307011A (es) Derivados hidrosolubles de camptotecina, proceso para su preparacion y composiciones farmaceuticas que los contienen.
BR0207487A (pt) Método de tratamento de tumores em mamìferos e uso de compostos de epotilona
BR9608488A (pt) Uso de derivados da vitamina d4 no tratamento de câncer
TR200101633T2 (tr) Farmasötik bileşim
AR043071A1 (es) Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
ES2192878T3 (es) 4,5-azolo-oxindoles.
IT9019793A0 (it) Composizioni farmaceutiche contenenti ipriflavone,procedimento per la loro preparazione e relativo impiego terapeutico
OA07029A (fr) Le chlorure de gallium, nouveau médicament anti-cancéreux.
UY26498A1 (es) Pirroles sustituidos

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 526608

Country of ref document: ES